InsiderTrades.com logo
Vikas Sinha net worth and biography
  • Phone
  • Email
  • Website

Vikas Sinha Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share

Mr Sinha has over 20 years of experience working in executive finance roles in the life sciences industry. Mr Sinha is Co-founder and Chief Financial Officer of ElevateBio, a holding company focused on building cell and gene therapy companies. He served as President and Chief Financial Officer of AlloVir, an ElevateBio portfolio company, from September 2018 to March 2025. From 2005 to 2016, he was the Chief Financial Officer of Alexion Pharmaceuticals. Prior to joining Alexion, Mr Sinha held various positions with Bayer across the world including CFO, Bayer North America and CFO Bayer Yakuhin, Japan. Mr Sinha holds an MBA in business administration from the Asian Institute of Management. He is a qualified Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant in the US.

What is Vikas Sinha's net worth?

The estimated net worth of Vikas Sinha is at least $10.06 million as of August 1st, 2025. Mr. Sinha owns 94,112 shares of Verona Pharma PLC American Depositary Share stock worth more than $10,061,514 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Sinha may own. Learn More about Vikas Sinha's net worth.

How do I contact Vikas Sinha?

The corporate mailing address for Mr. Sinha and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Vikas Sinha's contact information.

Has Vikas Sinha been buying or selling shares of Verona Pharma PLC American Depositary Share?

Vikas Sinha has not been actively trading shares of Verona Pharma PLC American Depositary Share in the last ninety days. Most recently, Vikas Sinha sold 4,328 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $56,869.92. Following the completion of the sale, the director now directly owns 94,112 shares of the company's stock, valued at $1,236,631.68. Learn More on Vikas Sinha's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Vikas Sinha Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell4,328$13.14$56,869.9294,112View SEC Filing Icon  
4/29/2025Sell20,000$8.92$178,400.0074,440View SEC Filing Icon  
See Full Table

Vikas Sinha Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Vikas Sinha's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05